# Resource Summary Report

Generated by nidm-terms on Aug 30, 2026

## CD38-PE, human

RRID:AB_2660381
Type: Antibody

### Proper Citation

Miltenyi Biotec Cat# 130-098-907, RRID:AB_2660381

### Antibody Information

**URL:** http://antibodyregistry.org/AB_2660381

**Proper Citation:** Miltenyi Biotec Cat# 130-098-907, RRID:AB_2660381

**Target Antigen:** CD38

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Discontinued: 7-2018; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreas, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-989. (RRID:AB_2733812).

**Antibody Name:** CD38-PE, human

**Description:** This monoclonal targets CD38

**Target Organism:** human

**Clone ID:** IB6

**Antibody ID:** AB_2660381

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-098-907

**Record Creation Time:** 20250819T223147+0000

**Record Last Update:** 20250820T022853+0000

## Ratings and Alerts

No rating or validation information has been found for CD38-PE, human.

Warning: Discontinued: 2021
Discontinued: 7-2018; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreas, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-989. (RRID:AB_2733812).

## Data and Source Information

**Source:** Antibody Registry

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at nidm-terms .

Liu C, et al. (2022) Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. Cell metabolism, 34(6), 818.